Trending NewsTrending NewsNASDAQ:URGN UroGen Pharma (URGN) Stock Price, News & Analysis $7.02 -0.35 (-4.75%) Closing price 06/9/2025 04:00 PM EasternExtended Trading$7.06 +0.05 (+0.64%) As of 07:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About UroGen Pharma Stock (NASDAQ:URGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get UroGen Pharma alerts:Sign Up Key Stats Today's Range$6.64▼$7.7250-Day Range$3.93▼$11.6452-Week Range$3.42▼$20.70Volume5.08 million shsAverage Volume841,300 shsMarket Capitalization$323.67 millionP/E RatioN/ADividend YieldN/APrice Target$23.14Consensus RatingModerate Buy Company OverviewUroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.Read More… UroGen Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks84th Percentile Overall ScoreURGN MarketRank™: UroGen Pharma scored higher than 84% of companies evaluated by MarketBeat, and ranked 315th out of 1,886 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingUroGen Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageUroGen Pharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about UroGen Pharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for UroGen Pharma are expected to decrease in the coming year, from ($3.12) to ($3.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of UroGen Pharma is -2.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of UroGen Pharma is -2.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about UroGen Pharma's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted25.11% of the float of UroGen Pharma has been sold short.Short Interest Ratio / Days to CoverUroGen Pharma has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in UroGen Pharma has recently increased by 11.35%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldUroGen Pharma does not currently pay a dividend.Dividend GrowthUroGen Pharma does not have a long track record of dividend growth. Sustainability and ESG4.5 / 5Environmental Score-1.33 Percentage of Shares Shorted25.11% of the float of UroGen Pharma has been sold short.Short Interest Ratio / Days to CoverUroGen Pharma has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in UroGen Pharma has recently increased by 11.35%, indicating that investor sentiment is decreasing significantly. News and Social Media2.8 / 5News Sentiment0.01 News SentimentUroGen Pharma has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 52 news articles for UroGen Pharma this week, compared to 5 articles on an average week.Search Interest10 people have searched for URGN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows6 people have added UroGen Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, UroGen Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.10% of the stock of UroGen Pharma is held by insiders.Percentage Held by Institutions91.29% of the stock of UroGen Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about UroGen Pharma's insider trading history. Receive URGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for UroGen Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address URGN Stock News HeadlinesShareholders that lost money on UroGen Pharma Ltd.(URGN) should contact Levi & Korsinsky about pending Class Action - URGNJune 10 at 5:45 AM | prnewswire.comThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 28, 2025 in UroGen Pharma Ltd. Lawsuit – URGNJune 9 at 1:36 PM | globenewswire.comBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly positioning itself to overthrow the entire banking system.June 10, 2025 | Crypto 101 Media (Ad)UroGen Pharma Ltd. (URGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitJune 9 at 1:18 PM | gurufocus.comROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages UroGen Pharma Ltd. ...June 9 at 12:20 PM | gurufocus.comUroGen Pharma Ltd. (URGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitJune 9 at 12:00 PM | prnewswire.comROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages UroGen Pharma Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action – URGNJune 9 at 11:58 AM | globenewswire.comUroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA's Briefing Document and ...June 9 at 10:25 AM | gurufocus.comSee More Headlines URGN Stock Analysis - Frequently Asked Questions How have URGN shares performed this year? UroGen Pharma's stock was trading at $10.65 at the beginning of the year. Since then, URGN shares have decreased by 34.1% and is now trading at $7.02. View the best growth stocks for 2025 here. How were UroGen Pharma's earnings last quarter? UroGen Pharma Ltd. (NASDAQ:URGN) announced its quarterly earnings data on Monday, May, 12th. The company reported ($0.92) EPS for the quarter, missing analysts' consensus estimates of ($0.83) by $0.09. The business earned $20.25 million during the quarter, compared to the consensus estimate of $22.71 million. Read the conference call transcript. When did UroGen Pharma IPO? UroGen Pharma (URGN) raised $46 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 3,500,000 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers. Who are UroGen Pharma's major shareholders? Top institutional shareholders of UroGen Pharma include UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC (9.46%), RA Capital Management L.P. (6.95%), Vestal Point Capital LP (4.67%) and Nantahala Capital Management LLC (2.96%). Insiders that own company stock include Mark Schoenberg and Jason Drew Smith. View institutional ownership trends. How do I buy shares of UroGen Pharma? Shares of URGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of UroGen Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that UroGen Pharma investors own include Voyager Therapeutics (VYGR), AUO (AUOTY), Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings5/12/2025Today6/10/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:URGN CIK1668243 Webwww.urogen.com Phone(646) 768-9780FaxN/AEmployees200Year FoundedN/APrice Target and Rating Average Stock Price Target$23.14 High Stock Price Target$55.00 Low Stock Price Target$3.00 Potential Upside/Downside+229.7%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($3.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$102.24 million Net Margins-129.11% Pretax Margin-124.59% Return on EquityN/A Return on Assets-47.94% Debt Debt-to-Equity Ratio4.77 Current Ratio9.00 Quick Ratio8.77 Sales & Book Value Annual Sales$91.87 million Price / Sales3.52 Cash FlowN/A Price / Cash FlowN/A Book Value($2.78) per share Price / Book-2.53Miscellaneous Outstanding Shares46,107,000Free Float22,258,000Market Cap$323.67 million OptionableOptionable Beta0.40 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:URGN) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWhy 2026 will be a disaster for many Americans2025 Market Crash The first-quarter stock crash left investors wondering what lies ahead. Today 50-year Wal...Chaikin Analytics | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredElon’s “Secret Mission”Tesla, SpaceX and Starlink made billions for investors... But a meeting Elon had on March 21st, 2025, could...Behind the Markets | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UroGen Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share UroGen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.